leisure time -WSS

leisure time

author：fashion 2025-09-30 00:51:33 - browse：7

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

entertainment

WSS

SEC charges former device maker CEO with $41 million fraud

Violet CEO on training clinicians to promote more inclusive care

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Editas, Vertex strike deal on CRISPR

David Ricks of Eli Lilly: best biopharma CEO of 2023

Can sheer will power keep patients alive in their dying hours?

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Heart attack and stroke risk calculators need revising

Carvykti CAR

Drug repurposing or repositioning? The language matters

After affirmative action ruling, medical educators look to 'holistic review'

Malaria cases in Florida and Texas: Here’s what you need to know

Wildfire smoke exposes gaps in outdoor worker protections

In age of alternative facts, a scholarly course on calling out crap

BioMarin wins approval for gene therapy to treat hemophilia A

ChatGPT in medicine: STAT answers readers' burning questions

Walensky prepares to leave CDC — and Congress — behind

hotspot

What STAT readers think about the FDA and patient advocacy

Medicare drug price negotiation hasn't dried up venture capital

Hospitals owned by private equity see complications spike 25%

Supreme Court strikes down use of affirmative action

Three trends to watch in biotech in 2024

Why health records don't always know when patients are dead

focus

entertainment

explore

focus